Fig. 7: Amelioration of murine MASH progression and steatosis in human liver graft via blocking Golgi PtdIns4P generation.

a, Schematic illustration of experiment design to administer UCB9608 to wild-type mice after induction of MASH via HFD, high-glucose/fructose-containing water and thermoneutral housing. b, BW gain during the period of UCB9608 treatment (n = 10 mice per group). c, EchoMRI analyses of lean mass, fat mass and BW to the MASH mice (n = 10 mice per group). d,e, Plasma FFA levels (d) and TG levels (e) 12 weeks after administration of UCB9608 (n = 10 mice per group). f, Alanine transaminase (ALT) and aspartate aminotransferase (AST) activity in the plasma from MASH mice after administration of UCB9608 (n = 10 mice per group). g, Liver mass/BW ratio of MASH mice after administration of UCB9608 (n = 10 mice per group). h, Determination of hepatic TG levels of MASH mice after administration of UCB9608 (n = 10 mice per group). i, Representative images of H&E staining, ORO staining and Gomori Green Trichome staining. Scale bar, 25 μm. Representative images from ten mice per group with similar results. j, Histology score of livers from MASH mice treated by DMSO and UCB9608 (n = 10 mice per group). k,l, Transcript levels of inflammatory markers (k) and fibrosis markers (l) in MASH livers as determined by qPCR (n = 10 mice per group). m, Schematic illustration of experiment design to administer UCB9608 to a human liver graft ex vivo during normothermic machine perfusion. n,o, Immunoblot of ATGL protein and quantification of TG levels in the human liver biopsies taken at different timepoints from both lobes. Three times repeated technically with similar results. Results are shown as mean ± s.e.m. and analysed using two-tailed unpaired t-test (b–g and k (Ccl2 and Tnfα) and l (Col1a2, Timp1 and Acta2)), two-tailed Mann–Whitney test (h, j and k (Emr1and Il1b) and l (Tgfb1 and Col1a1)) and two-tailed Pearson’s correlation (o). Source numerical data and unprocessed blots are available in .

Source data